Medical Condition News

RSS

Linagliptin does not offer added benefit for adults with type 2 diabetes

Linagliptin has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise.

7 Jan 2012

SPIE to honor CCNY professor with Britton Chance Biomedical Optics Award

A scientific innovator from The City College of New York (CCNY) whose research unites the divergent fields of medicine, biology and high-speed laser physics will be honored this month for his pioneering work in biomedical optics by SPIE, the international society for optics and photonics.

7 Jan 2012

PCI Biotech focuses on localised cancer therapy with minimum side effects

Side effects are currently the biggest problem with any cancer treatment. A Norwegian biotech company is drawing closer to the goal of creating a treatment which kills only cancer cells, leaving other cells unaffected.

7 Jan 2012

VisionGate achieves full automation of Cell-CT system

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer and other applications, today reported that it has achieved full automation of its Cell-CT system, a proprietary imaging platform that generates high-resolution 3D biosignatures from intact cells.

7 Jan 2012

Studies identify genes and small molecules against protein conformational diseases

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes.

7 Jan 2012

Pearl Therapeutics completes two PT003 Phase 2b clinical studies on COPD

Pearl Therapeutics Inc. today announced the completion of two Phase 2b clinical studies of PT003, the Company's investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD.

7 Jan 2012

Study on benefits of Brain Wave Vibration meditation method

BEST Life Media, publisher of the Award Winning Brain Wave Vibration, and other books on health and wellness and the mind-body connection, is pleased to announce the results of a recent study concerning the Brain Wave Vibration meditation method.

7 Jan 2012

Supernus secures $42M through two transactions

Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million.

7 Jan 2012

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

7 Jan 2012

Scientists map neurons that process different kinds of visual information

There's a 3-D world in our brains. It's a landscape that mimics the outside world, where the objects we see exist as collections of neural circuits and electrical impulses.

7 Jan 2012

Positive topline results from Civitas' CVT-301 Phase 1 trial on PD

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today positive topline results from a Phase 1 clinical trial for CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations associated with Parkinson's disease.

7 Jan 2012

FDG-PET safe and accurate in detecting dementia, Alzheimer's

In a new review of imaging studies spanning more than ten years, scientists find that a method of positron emission tomography (PET) safely and accurately detects dementia, including the most common and devastating form among the elderly, Alzheimer's disease.

7 Jan 2012

CMS assigns permanent J-code for Savient's KRYSTEXXA to treat RCG

Savient Pharmaceuticals, Inc. today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA (pegloticase) became available on January 1, 2012.

7 Jan 2012

KAI commences enrollment in KAI-4169 second Phase 2 study for CKD-MBD

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease.

6 Jan 2012

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo Pharmaceuticals announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine.

6 Jan 2012

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

ChemoCentryx, Inc., today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).

6 Jan 2012

Non-eosinophilic disease more prevalent in patients with mild-to-moderate asthma

A large percentage of patients with mild-to-moderate asthma have persistently non-eosinophilic disease which may not respond to currently available anti-inflammatory treatments, according to a new study.

6 Jan 2012

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

BioDelivery Sciences International, Inc. today announced the signing of a worldwide license and development agreement with Endo Pharmaceuticals for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain.

6 Jan 2012

Muscles must work too inefficiently to speed walk

Other than Olympic race walkers, people generally find it more comfortable to run than walk when they start moving at around 2 meters per second - about 4.5 miles per hour.

6 Jan 2012

Scottsdale Healthcare is first in Arizona to perform TAVR procedure

Scottsdale Healthcare Osborn Medical Center is the first hospital in Arizona to perform a new nonsurgical heart valve replacement procedure, the Transcatheter Aortic Valve Replacement (TAVR). TAVR valves are inserted via a catheter through the femoral artery, without requiring open heart surgery.

6 Jan 2012